Ultrafast CT developer Imatron of South San Francisco, CA, hasreceived a major cash infusion through a $9 million equity placementto a group of institutional investors based in Switzerland. Thevendor said the funds would be used to develop international
Ultrafast CT developer Imatron of South San Francisco, CA, hasreceived a major cash infusion through a $9 million equity placementto a group of institutional investors based in Switzerland. Thevendor said the funds would be used to develop international markets,establish a clinical research and customer demonstration facilityin the San Francisco area and support additional research andclinical applications for its technology.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.